Top

Clinical Reviews in Allergy & Immunology

Published in:

01-12-2020 | Systemic Lupus Erythematosus

Autoimmunity in 2019

Author: Carlo Selmi

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2020

Abstract

Based on the PubMed data, we have been performing a yearly evaluation of the publications related to autoimmune diseases and immunology to ascertain the relative weight of the former in the scientific literature. It is particularly intriguing to observe that despite the numerous new avenues of immune-related mechanisms, such as cancer immunotherapy, the proportion of immunology manuscripts related to autoimmunity continues to increase and has been approaching 20% in 2019. As in the previous 13 years, we performed an arbitrary selection of the peer-reviewed articles published by the major dedicated Journals and discussed the common themes which continue to outnumber peculiarites in autoimmune diseases. The investigated areas included systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), autoantibodies (autoAbs), and common therapeutic avenues and novel pathogenic mechanisms for autoimmune conditions. Some examples include new pathogenetic evidence which is well represented by IL21 or P2X7 receptor (P2X7R) in SLE or the application of single-cell RNA sequencing (scRNA-seq), mass cytometry, bulk RNA sequencing (RNA-seq), and flow cytometry for the analysis of different cellular populations in RA. Cumulatively and of interest to the clinicians, a large number of findings continue to underline the importance of a strict relationship between basic and clinical science to define new pathogenetic and therapeutic developments. The therapeutic pipeline in autoimmunity continues to grow and maintain a constant flow of new molecules, as well illustrated in RA and PsA, and this is most certainly derived from the new basic evidence and the high-throughput tools applied to autoimmune diseases.

Zanatta E, Famoso G, Boscain F, Montisci R, Pigatto E, Polito P et al (2019) Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: a newsworthy association. Autoimmun Rev 18:177–183PubMedCrossRef

Yao Q, Song Z, Wang B, Zhang JA, Mu K (2019) Thyroid disorders in patients with systemic sclerosis: a systematic review and meta-analysis. Autoimmun Rev 18:634–636PubMedCrossRef

Suto T, Karonitsch T (2020) The immunobiology of mTOR in autoimmunity. J Autoimmun 110:102373PubMedCrossRef

Smith V, Vanhaecke A, Herrick AL, Distler O, Guerra MG, Denton CP et al (2019) Fast track algorithm: how to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". Autoimmun Rev 18:102394PubMedCrossRef

Sciascia S, Cecchi I, Massara C, Rossi D, Radin M, Ladehesa PL et al (2020) Thermography in systemic sclerosis patients and other rheumatic diseases: diagnosis, disease activity assessment, and therapeutic monitoring. Autoimmun Rev 19:102449PubMedCrossRef

Riccardi A, Marcoccia A, Borgia A, Guastafierro T, Bondanini F, Fasano S et al (2019) Undifferentiated connective tissue disease at risk of systemic sclerosis: a weighted score to identify patients who will evolve. Autoimmun Rev 18:102358PubMedCrossRef

Narvaez J, Pirola JP, LLuch J, Juarez P, Nolla JM, Valenzuela A (2019) Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: a case series and systematic review of the literature. Autoimmun Rev 18:262–269PubMedCrossRef

Napodano C, Pocino K, Rigante D, Stefanile A, Gulli F, Marino M et al (2019) Free light chains and autoimmunity. Autoimmun Rev 18:484–492PubMedCrossRef

Molano-Gonzalez N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodriguez Y et al (2019) Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun 98:24–32PubMedCrossRef

10.

Meridor K, Levy Y (2020) Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature. Autoimmun Rev 19:102439PubMedCrossRef

11.

Marie I (2019) Systemic sclerosis and exposure to heavy metals. Autoimmun Rev 18:62–72PubMedCrossRef

12.

Jafarinejad-Farsangi S, Gharibdoost F, Farazmand A, Kavosi H, Jamshidi A, Karimizadeh E et al (2019) MicroRNA-21 and microRNA-29a modulate the expression of collagen in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity 52:108–116PubMedCrossRef

13.

Henry TW, Mendoza FA, Jimenez SA (2019) Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. Autoimmun Rev 18:102396PubMedCrossRef

14.

Frantz C, Huscher D, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G et al (2020) Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database. Autoimmun Rev 19:102452PubMedCrossRef

15.

Chaigne B, Rodeia S, Benmostefa N, Berezne A, Authier J, Cohen P et al (2020) Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients. Autoimmun Rev 19:102431PubMedCrossRef

16.

Cattalini M, Soliani M, Caparello MC, Cimaz R (2019) Sex differences in pediatric rheumatology. Clin Rev Allergy Immunol 56:293–307PubMedCrossRef

17.

Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L (2019) Is there today a place for corticosteroids in the treatment of scleroderma? Autoimmun Rev 18:102403PubMedCrossRef

18.

Bellan M, Patrucco F, Barone-Adesi F, Gavelli F, Castello LM, Nerviani A et al (2020) Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: a systematic review. Autoimmun Rev 19:102453PubMedCrossRef

19.

Barrat FJ, Crow MK, Ivashkiv LB (2019) Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol 20:1574–1583PubMedPubMedCentralCrossRef

20.

Lescoat A, Ballerie A, Jouneau S, Fardel O, Vernhet L, Jego P et al (2019) M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis. Ann Rheum Dis 78:e127PubMedCrossRef

21.

Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD et al (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79:379–386PubMedCrossRef

22.

Skarstein K, Jensen JL, Galtung H, Jonsson R, Brokstad K, Aqrawi LA (2019) Autoantigen-specific B cells and plasma cells are prominent in areas of fatty infiltration in salivary glands of patients with primary Sjogren's syndrome. Autoimmunity 52:242–250PubMedCrossRef

23.

Shin JI, Lee KH, Joo YH, Lee JM, Jeon J, Jung HJ et al (2019) Inflammasomes and autoimmune and rheumatic diseases: a comprehensive review. J Autoimmun 103:102299PubMedCrossRef

24.

Martin-Nares E, Hernandez-Molina G (2019) Novel autoantibodies in Sjogren's syndrome: a comprehensive review. Autoimmun Rev 18:192–198PubMedCrossRef

25.

Malagon C, Gomez MDP, Mosquera C, Vargas C, Gonzalez T, Arango C et al (2019) Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev 18:369–381PubMedCrossRef

26.

Long D, Chen Y, Wu H, Zhao M, Lu Q (2019) Clinical significance and immunobiology of IL-21 in autoimmunity. J Autoimmun 99:1–14PubMedCrossRef

27.

Huang C, Zhu HX, Yao Y, Bian ZH, Zheng YJ, Li L et al (2019) Immune checkpoint molecules Possible future therapeutic implications in autoimmune diseases. J Autoimmun 104:102333PubMedCrossRef

28.

Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S et al (2019) The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): review of the literature and report of a large series. Autoimmun Rev 18:287–292PubMedCrossRef

29.

Clancy RM, Marion MC, Ainsworth HC, Blaser MJ, Chang M, Howard TD et al (2020) Salivary dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus. J Autoimmun 107:102354PubMedCrossRef

30.

Clancy RM, Halushka M, Rasmussen SE, Lhakhang T, Chang M, Buyon JP (2019) Siglec-1 macrophages and the contribution of IFN to the development of autoimmune congenital heart block. J Immunol 202:48–55PubMedCrossRef

31.

Applbaum E, Lichtbroun A (2019) Novel Sjogren's autoantibodies found in fibromyalgia patients with sicca and/or xerostomia. Autoimmun Rev 18:199–202PubMedCrossRef

32.

Anaya JM, Restrepo-Jimenez P, Rodriguez Y, Rodriguez-Jimenez M, Acosta-Ampudia Y, Monsalve DM et al (2019) Sjogren's syndrome and autoimmune thyroid disease: two sides of the same coin. Clin Rev Allergy Immunol 56:362–374PubMedCrossRef

33.

Dorner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM et al (2019) Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis 78:641–647PubMedCrossRef

34.

Ramos-Casals M, Brito-Zeron P, Bombardieri S, Bootsma H, De Vita S, Dorner T et al (2020) EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis 79:3–18PubMedCrossRef

35.

van der Meulen TA, van Nimwegen JF, Harmsen HJM, Liefers SC, van der Tuuk K, Kroese FGM et al (2019) Normal vaginal microbiome in women with primary Sjogren's syndrome-associated vaginal dryness. Ann Rheum Dis 78:707–709PubMedCrossRef

36.

Lee J, Baek S, Koh JH, Kim JW, Kim SY, Chung SH et al (2019) Soluble siglec-5 is a novel salivary biomarker for primary Sjogren's syndrome. J Autoimmun 100:114–119PubMedCrossRef

37.

Wu X, Liu Y, Wei W, Liu ML (2019) Extracellular vesicles in autoimmune vasculitis - little dirts light the fire in blood vessels. Autoimmun Rev 18:593–606PubMedPubMedCentralCrossRef

38.

Watanabe-Kusunoki K, Nakazawa D, Kusunoki Y, Kudo T, Hattanda F, Nishio S et al (2020) Recombinant thrombomodulin ameliorates autoimmune vasculitis via immune response regulation and tissue injury protection. J Autoimmun 108:102390PubMedCrossRef

39.

Wang C, Deng H, Gong Y, You R, Chen M, Zhao MH (2020) Effect of high mobility group box 1 on toll-like receptor 9 in B cells in myeloperoxidase-ANCA-associated vasculitis. Autoimmunity 53:28–34PubMedCrossRef

40.

Walls CA, Basu N, Hutcheon G, Erwig LP, Little MA, Kidder D (2020) A novel 4-dimensional live-cell imaging system to study leukocyte-endothelial dynamics in ANCA-associated vasculitis. Autoimmunity 53:148–155PubMedCrossRef

41.

Tahvildari M, Dana R (2019) Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J Immunol 203:2749–2755PubMedCrossRef

42.

Hamano Y, Ito F, Suzuki O, Koura M, Matsuoka S, Kobayashi T et al (2019) Vasculitis and crescentic glomerulonephritis in a newly established congenic mouse strain derived from ANCA-associated vasculitis-prone SCG/Kj mice. Autoimmunity 52:208–219PubMedCrossRef

43.

Frangou E, Vassilopoulos D, Boletis J, Boumpas DT (2019) An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment. Autoimmun Rev 18:751–760PubMedCrossRef

44.

Enocsson H, Wirestam L, Dahle C, Padyukov L, Jonsen A, Urowitz MB et al (2020) Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun 106:102340PubMedCrossRef

45.

Dolff S, Witzke O, Wilde B (2019) Th17 cells in renal inflammation and autoimmunity. Autoimmun Rev 18:129–136PubMedCrossRef

46.

Klapa S, Muller A, Koch A, Heidecke H, Kahler W, Junker J et al (2019) Decreased endothelin receptor A autoantibody levels are associated with early ischaemic events in patients with giant-cell arteritis. Ann Rheum Dis 78:1443–1444PubMedCrossRef

47.

Kong X, Sawalha AH (2019) Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis 78:1388–1397PubMedCrossRef

48.

Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC (2020) Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis. Ann Rheum Dis 79:262–267PubMedCrossRef

49.

Vandergheynst FA, Lelubre C (2019) Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al. Annals of the rheumatic diseases

50.

Dieudonne Y, Gies V, Guffroy A, Keime C, Bird AK, Liesveld J et al (2019) Transitional B cells in quiescent SLE: an early checkpoint imprinted by IFN. J Autoimmun 102:150–158PubMedPubMedCentralCrossRef

51.

Pisetsky DS (2020) Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun 110:102356PubMedCrossRef

52.

Franks SE, Getahun A, Cambier JC (2019) A precision B cell-targeted therapeutic approach to autoimmunity caused by phosphatidylinositol 3-kinase pathway dysregulation. J Immunol 202:3381–3393PubMedCrossRef

53.

Feng Y, Yang M, Wu H, Lu Q (2020) The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical. Autoimmunity 53:56–64PubMedCrossRef

54.

Cao F, Hu LQ, Yao SR, Hu Y, Wang DG, Fan YG et al (2019) P2X7 receptor: a potential therapeutic target for autoimmune diseases. Autoimmun Rev 18:767–777PubMedCrossRef

55.

Pernis AB, Ivashkiv LB (2019) ‘-Omics’ shed light on B cells in lupus. Nat Immunol 20:946–948PubMedCrossRef

56.

Cunningham MA, Richard ML, Wirth JR, Scott JL, Eudaly J, Ruiz P et al (2019) Novel mechanism for estrogen receptor alpha modulation of murine lupus. J Autoimmun 97:59–69PubMedCrossRef

57.

Syrett CM, Sierra I, Beethem ZT, Dubin AH, Anguera MC (2020) Loss of epigenetic modifications on the inactive X chromosome and sex-biased gene expression profiles in B cells from NZB/W F1 mice with lupus-like disease. J Autoimmun 107:102357PubMedCrossRef

58.

Lownik JC, Wimberly JL, Conrad DH, Martin RK (2019) B cell ADAM10 controls murine lupus progression through regulation of the ICOS:ICOS ligand axis. J Immunol 202:664–674PubMedCrossRef

59.

Giltiay NV, Giordano D, Clark EA (2019) The plasticity of newly formed B cells. J Immunol 203:3095–3104PubMedCrossRef

60.

Liu X, Zhang W, Zhao M, Fu L, Liu L, Wu J et al (2019) T cell receptor beta repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 78:1070–1078PubMedCrossRef

61.

Frangou E, Chrysanthopoulou A, Mitsios A, Kambas K, Arelaki S, Angelidou I et al (2019) REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann Rheum Dis 78:238–248PubMedCrossRef

62.

Linge P, Arve S, Olsson LM, Leonard D, Sjowall C, Frodlund M et al (2020) NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. Ann Rheum Dis 79:254–261PubMedCrossRef

63.

Odqvist L, Jevnikar Z, Riise R, Oberg L, Rhedin M, Leonard D et al (2019) Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann Rheum Dis 78:1363–1370PubMedCrossRef

64.

Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C (2020) A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheum 72:47–56CrossRef

65.

Curran CS, Gupta S, Sanz I, Sharon E (2019) PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun 97:1–9PubMedCrossRef

66.

Horuluoglu B, Bayik D, Kayraklioglu N, Goguet E, Kaplan MJ, Klinman DM (2019) PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus. J Autoimmun 99:24–32PubMedPubMedCentralCrossRef

67.

Panousis NI, Bertsias GK, Ongen H, Gergianaki I, Tektonidou MG, Trachana M et al (2019) Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis 78:1079–1089PubMedCrossRef

68.

Wang B, Chen S, Zheng Q, Gao Z, Chen R, Xuan J et al. (2019) Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus. Ann Rheum Dis

69.

Wang Y, Chen S, Chen J, Xie X, Gao S, Zhang C et al (2020) Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome highlight T cell-initiated autoimmunity. Ann Rheum Dis 79:268–275PubMedCrossRef

70.

Zhang SX, Wang J, Chen JW, Zhang MX, Zhang YF, Hu FY et al. (2019) The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus Ann Rheum Dis

71.

Zhao Z, Ren J, Dai C, Kannapell CC, Wang H, Gaskin F et al (2019) Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification. Ann Rheum Dis 78:380–390PubMedCrossRef

72.

Anaya-Macias BU, De la Cruz-Mosso U, Palafox-Sanchez CA, Parra-Rojas I, Martinez-Bonilla G, Gonzalez-Lopez L et al (2020) The -675 4G/5G PAI-1 polymorphism confers genetic susceptibility to systemic lupus erythematosus, its clinical manifestations, and comorbidities in Mexican-Mestizo population. Autoimmunity 53:71–77PubMedCrossRef

73.

Liu LN, Wang P, Zou YF, Xu Z, Cheng J, Zhang Y et al (2019) Semaphorin-3A, semaphorin-7A gene single nucleotide polymorphisms, and systemic lupus erythematosus susceptibility. Autoimmunity 52:161–167PubMedCrossRef

74.

Murdaca G, Tonacci A, Negrini S, Greco M, Borro M, Puppo F et al (2019) Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications. Autoimmun Rev 18:102350PubMedCrossRef

75.

Correa Freitas E, Evelyn Karnopp T, de Souza Silva JM, Cavalheiro do Espirito Santo R, da Rosa TH, de Oliveira MS et al (2019) Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model. Autoimmunity 52:69–77PubMedCrossRef

76.

Soni C, Sinha I, Fasnacht MJ, Olsen NJ, Rahman ZSM, Sinha R (2019) Selenium supplementation suppresses immunological and serological features of lupus in B6.Sle1b mice. Autoimmunity 52:57–68PubMedCrossRefPubMedCentral

77.

Briand C, Fremond ML, Bessis D, Carbasse A, Rice GI, Bondet V et al (2019) Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Ann Rheum Dis 78:431–433PubMedCrossRef

78.

Goropevsek A, Holcar M, Pahor A, Avcin T (2019) STAT signaling as a marker of SLE disease severity and implications for clinical therapy. Autoimmun Rev 18:144–154PubMedCrossRef

79.

Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL et al (2019) Adoptive Treg cell therapy in a patient with systemic lupus erythematosus. Arthritis Rheum 71:431–440CrossRef

80.

Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S et al (2019) Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 20:928–942PubMedPubMedCentralCrossRef

81.

Scheinecker C, Goschl L, Bonelli M (2020) Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun 110:102376PubMedCrossRef

82.

Cammarata I, Martire C, Citro A, Raimondo D, Fruci D, Melaiu O et al (2019) Counter-regulation of regulatory T cells by autoreactive CD8(+) T cells in rheumatoid arthritis. J Autoimmun 99:81–97PubMedCrossRef

83.

Ribon M, Seninet S, Mussard J, Sebbag M, Clavel C, Serre G et al (2019) Neutrophil extracellular traps exert both pro- and anti-inflammatory actions in rheumatoid arthritis that are modulated by C1q and LL-37. J Autoimmun 98:122–131PubMedCrossRef

84.

El Shikh MEM, El Sayed R, Nerviani A, Goldmann K, John CR, Hands R et al (2019) Extracellular traps and PAD4 released by macrophages induce citrullination and auto-antibody production in autoimmune arthritis. J Autoimmun 105:102297PubMedCrossRef

85.

Peene I, Elewaut D (2019) Changing the wolf from outside: how microbiota trigger systemic lupus erythematosus. Ann Rheum Dis 78:867–869PubMedCrossRef

86.

Silverman GJ, Azzouz DF (2019) Response to: 'The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus' by Zhang et al and the phylogeny of a candidate pathobiont in lupus nephritis. Ann Rheum Dis

87.

van Dijkhuizen EHP, Del Chierico F, Malattia C, Russo A, Pires Marafon D, Ter Haar NM et al (2019) Microbiome analytics of the gut microbiota in patients with juvenile idiopathic arthritis: a longitudinal observational cohort study. Arthritis Rheum 71:1000–1010CrossRef

88.

Asquith M, Sternes PR, Costello ME, Karstens L, Diamond S, Martin TM et al (2019) HLA alleles associated with risk of ankylosing spondylitis and rheumatoid arthritis influence the gut microbiome. Arthritis Rheum 71:1642–1650CrossRef

89.

Zhou C, Zhao H, Xiao XY, Chen BD, Guo RJ, Wang Q et al (2020) Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis. J Autoimmun 107:102360PubMedCrossRef

90.

Wells PM, Williams FMK, Matey-Hernandez ML, Menni C, Steves CJ (2019) RA and the microbiome: Do host genetic factors provide the link? J Autoimmun 99:104–115PubMedPubMedCentralCrossRef

91.

Zhao CN, Xu Z, Wu GC, Mao YM, Liu LN, Qian W et al (2019) Emerging role of air pollution in autoimmune diseases. Autoimmun Rev 18:607–614PubMedCrossRef

92.

Yang XK, Liu J, Chen SY, Li M, Zhang MM, Leng RX et al (2019) UBASH3A gene polymorphisms and expression profile in rheumatoid arthritis. Autoimmunity 52:21–26PubMedCrossRef

93.

Regueiro C, Rodriguez-Rodriguez L, Triguero-Martinez A, Nuno L, Castano-Nunez AL, Villalva A et al (2019) Specific association of HLA-DRB1*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis. Arthritis Rheum 71:331–339CrossRef

94.

Plant D, Maciejewski M, Smith S, Nair N, Hyrich K, Ziemek D et al (2019) Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheum 71:678–684CrossRef

95.

Shen F, Verma AH, Volk A, Jones B, Coleman BM, Loza MJ et al (2019) Combined blockade of TNF-alpha and IL-17A alleviates progression of collagen-induced arthritis without causing serious infections in mice. J Immunol 202:2017–2026PubMedCrossRef

96.

Lorenzetti R, Janowska I, Smulski CR, Frede N, Henneberger N, Walter L et al (2019) Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. J Autoimmun 101:145–152PubMedCrossRef

97.

De Santis M, Isailovic N, Generali E, Ceribelli A, Altamore L, Real-Fernandez F et al (2019) Humoral response against LL-37 in psoriatic disease: comment on the article by Yuan et al. Arthritis Rheum 71:1964–1965CrossRef

98.

Yuan Y, Qiu J, Lin ZT, Li W, Haley C, Mui UN et al (2019) Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheum 71:941–951CrossRef

99.

Sobchak C, Akhtari S, Harvey P, Gladman D, Chandran V, Cook R et al (2019) Value of carotid ultrasound in cardiovascular risk stratification in patients with psoriatic disease. Arthritis Rheum 71:1651–1659CrossRef

100.

Savage L, Goodfield M, Horton L, Watad A, Hensor E, Emery P et al (2019) Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis Rheum 71:626–631CrossRef

101.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al (2019) Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheum 71:5–32CrossRef

102.

Chattopadhyay A, Sharma SK, Naidu S, Dhir V (2019) Failure of etanercept and methotrexate combination therapy to surpass etanercept monotherapy in psoriatic arthritis-What about the joint counts? Comment on the Article by Mease et al. Arthritis Rheum 71:1965–1966CrossRef

103.

Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ (2019) Responsiveness of serum C-reactive protein, interleukin-17A, and interleukin-17F levels to ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double-blind, placebo-controlled trials. Arthritis Rheum 71:1660–1669CrossRef

104.

Merola JF, Ogdie A (2019) SEAM-PsA: seems like methotrexate works in psoriatic arthritis? Arthritis Rheum 71:1027–1029CrossRef

105.

Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L et al (2019) Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheum 71:1112–1124CrossRef

106.

Agrawal M, Shah S, Patel A, Pinotti R, Colombel JF, Burisch J (2019) Changing epidemiology of immune-mediated inflammatory diseases in immigrants: a systematic review of population-based studies. J Autoimmun 105:102303PubMedCrossRefPubMedCentral

107.

Bernink JH, Ohne Y, Teunissen MBM, Wang J, Wu J, Krabbendam L et al (2019) c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies. Nat Immunol 20:992–1003PubMedCrossRef

108.

Chimenti MS, Caso F, Alivernini S, De Martino E, Costa L, Tolusso B et al (2019) Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease. Autoimmun Rev 18:565–575PubMedCrossRef

109.

Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G et al (2019) In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 78:131–139PubMedCrossRef

110.

Betancur JF, Gomez-Puerta JA (2020) Antinuclear antibodies mitotic patterns and their clinical associations. Ann Rheum Dis 79:e63PubMedCrossRef

111.

Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ et al (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879–889PubMedCrossRef

112.

Deng C, Qu X, Cheng S, Zeng X, Li Y, Fei Y (2019) Decision-making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat? Ann Rheum Dis

113.

Greco M, Garcia de Yebenes MJ, Alarcon I, Brandy-Garcia AM, Rua-Figueroa I, Loza E et al (2020) Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco et al' by Knitza et al. Ann Rheum Dis 79:e87PubMedCrossRef

114.

Lee AYS, Beroukas D, Roberts-Thomson PJ (2020) Utility of the HEp-2000 antinuclear antibody substrate. Ann Rheum Dis 79:e67PubMedCrossRef

115.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR et al (2019) Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78:996–1002PubMedCrossRef

116.

Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988–995PubMedCrossRef

117.

Spielmann L, Nespola B, Severac F, Andres E, Kessler R, Guffroy A et al (2019) Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann Rheum Dis 78:1101–1106PubMedCrossRef

118.

van Delft MAM, van der Woude D, Toes REM, Trouw LA (2019) Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. Ann Rheum Dis 78:146–148PubMedCrossRef

119.

Vulsteke JB, Van Hoovels L, Willems P, Vander Cruyssen B, Vanderschueren S, Westhovens R et al. (2019) Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis

120.

Andrianova IA, Ponomareva AA, Mordakhanova ER, Le Minh G, Daminova AG, Nevzorova TA et al (2020) In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation. J Autoimmun 107:102355PubMedCrossRef

121.

Germar K, Fehres CM, Scherer HU, van Uden N, Pollastro S, Yeremenko N et al (2019) Generation and characterization of anti-citrullinated protein antibody-producing B cell clones from rheumatoid arthritis patients. Arthritis Rheum 71:340–350CrossRef

122.

Hoshino-Negishi K, Ohkuro M, Nakatani T, Kuboi Y, Nishimura M, Ida Y et al (2019) Role of anti-fractalkine antibody in suppression of joint destruction by inhibiting migration of osteoclast precursors to the synovium in experimental arthritis. Arthritis Rheum 71:222–231CrossRef

123.

Kelmenson LB, Wagner BD, McNair BK, Frazer-Abel A, Demoruelle MK, Bergstedt DT et al (2020) Timing of elevations of autoantibody isotypes prior to diagnosis of rheumatoid arthritis. Arthritis Rheum 72:251–261CrossRef

124.

Kongpachith S, Lingampalli N, Ju CH, Blum LK, Lu DR, Elliott SE et al (2019) Affinity maturation of the anti-citrullinated protein antibody paratope drives epitope spreading and polyreactivity in rheumatoid arthritis. Arthritis Rheum 71:507–517CrossRef

125.

Lo KC, Sullivan E, Bannen RM, Jin H, Rowe M, Li H et al (2020) Comprehensive profiling of the rheumatoid arthritis antibody repertoire. Arthritis Rheum 72:242–250CrossRef

126.

Schwenzer A, Quirke AM, Montgomery AB, Venables PJ, Sayles HR, Schlumberger W et al (2019) Time to include fine specificity anti-citrullinated protein antibodies in the routine diagnosis and management of rheumatoid arthritis? Arthritis Rheum 71:476–478CrossRef

127.

Shelef MA (2019) New relationships for old autoantibodies in rheumatoid arthritis. Arthritis Rheum 71:1396–1399CrossRef

128.

Zheng Z, Mergaert AM, Fahmy LM, Bawadekar M, Holmes CL, Ong IM et al (2020) Disordered antigens and epitope overlap between anti-citrullinated protein antibodies and rheumatoid factor in rheumatoid arthritis. Arthritis Rheum 72:262–272CrossRef

129.

Ge C, Xu B, Liang B, Lonnblom E, Lundstrom SL, Zubarev RA et al (2019) Structural basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis Rheum 71:210–221CrossRef

130.

Hafkenscheid L, de Moel E, Smolik I, Tanner S, Meng X, Jansen BC et al (2019) N-linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis. Arthritis Rheum 71:1626–1633CrossRef

131.

Holmdahl R (2019) The specificity of monoclonal anti-citrullinated protein antibodies: comment on the article by Steen et al. Arthritis Rheum 71:324–325CrossRef

132.

Jain A, Shah H, Simonsick EM, Metter EJ, Mangold L, Humphreys E et al (2019) Angiotensin receptor autoantibodies as exposures that modify disease progression: cross sectional, longitudinal and in vitro studies of prostate cancer. J Transl Autoimmun 2

133.

Stathopoulos P, Chastre A, Waters P, Irani S, Fichtner ML, Benotti ES et al (2019) Autoantibodies against neurologic antigens in nonneurologic autoimmunity. J Immunol 202:2210–2219PubMedPubMedCentralCrossRef

134.

Fresquet M, Rhoden SJ, Jowitt TA, McKenzie EA, Roberts I, Lennon R et al (2020) Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain. J Autoimmun 106:102308PubMedPubMedCentralCrossRef

135.

Alhomaidan HT, Rasheed N, Almatrafi S, Al-Rashdi FH, Rasheed Z (2019) Bisphenol A modified DNA: a possible immunogenic stimulus for anti-DNA autoantibodies in systemic lupus erythematosus. Autoimmunity 52:272–280PubMedCrossRef

136.

Acosta-Herrera M, Kerick M, Gonzalez-Serna D, Wijmenga C, Franke A, Gregersen PK et al (2019) Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. Ann Rheum Dis 78:311–319PubMedCrossRef

137.

Akizuki S, Ishigaki K, Kochi Y, Law SM, Matsuo K, Ohmura K et al (2019) PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Ann Rheum Dis 78:509–518PubMedCrossRef

138.

Tkachenko O, Lapin S, Maslyansky A, Myachikova V, Guseva V, Belolipetskaia E et al (2019) Influence of HLA-DRB1 susceptibility alleles on the autoantibodies spectrum of systemic lupus erythematosus in European part of Russia. Autoimmun Rev 18:558–560PubMedCrossRef

139.

Shah AA, Laiho M, Rosen A, Casciola-Rosen L (2019) Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma. Arthritis Rheum 71:1571–1579CrossRef

140.

Pinal-Fernandez I, Amici DR, Parks CA, Derfoul A, Casal-Dominguez M, Pak K et al (2019) Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity. Arthritis Rheum 71:1371–1376CrossRef

141.

Mosanya CH, Isaacs JD (2019) Tolerising cellular therapies: what is their promise for autoimmune disease? Ann Rheum Dis 78:297–310PubMedCrossRef

142.

Scheinberg M, Azevedo V (2019) The future landscape of biosimilars in rheumatology: Where we are where we are going. Autoimmun Rev 18:203–208PubMedCrossRef

143.

Muhammad Yusoff F, Wong KK, Mohd Redzwan N (2020) Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity 53:8–20PubMedCrossRef

144.

Rahman S, Sagar D, Hanna RN, Lightfoot YL, Mistry P, Smith CK et al (2019) Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis 78:957–966PubMedCrossRef

145.

Chan KK, Bass AR (2019) Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor. Ann Rheum Dis 78:e70PubMedCrossRef

146.

Delyon J, Brunet-Possenti F, Leonard-Louis S, Arangalage D, Baudet M, Baroudjian B et al (2019) Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. Ann Rheum Dis 78:e129PubMedCrossRef

147.

Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C et al (2019) Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis 78:860–862PubMedCrossRef

148.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN et al (2019) Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 78:150–152PubMedCrossRef

149.

Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL et al (2019) Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis 78:e67PubMedCrossRef

150.

Schaeverbeke T, Kostine M (2019) Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and Moura. Ann Rheum Dis 78:e92PubMedCrossRef

151.

McGonagle D, Bragazzi NL, Amital H, Watad A (2020) Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival. Autoimmun Rev 19:102456PubMedCrossRef

152.

Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T et al (2019) Targeting the immune complex-bound complement C3d ligand as a novel therapy for lupus. J Immunol 203:3136–3147PubMedPubMedCentralCrossRef

153.

Khan H, Sureda A, Belwal T, Cetinkaya S, Suntar I, Tejada S et al (2019) Polyphenols in the treatment of autoimmune diseases. Autoimmun Rev 18:647–657PubMedPubMedCentralCrossRef

154.

Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A (2020) High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy. Arthritis Rheum 72:20–30CrossRef

155.

Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM (2019) A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 71:1437–1449CrossRef

156.

Liao KP, Solomon DH (2019) Lipids and cardiovascular risk through the lens of rheumatoid arthritis. Arthritis Rheum 71:1393–1395CrossRef

157.

Lopez-Mejias R, Carmona FD, Genre F, Remuzgo-Martinez S, Gonzalez-Juanatey C, Corrales A et al (2019) Identification of a 3'-untranslated genetic variant of RARB associated with carotid intima-media thickness in rheumatoid arthritis: a genome-wide association study. Arthritis Rheum 71:351–360CrossRef

158.

Pellicciotta M, Rigoni R, Falcone EL, Holland SM, Villa A, Cassani B (2019) The microbiome and immunodeficiencies: lessons from rare diseases. J Autoimmun 98:132–148PubMedCrossRef

159.

Croci S, Bonacini M, Muratore F, Caruso A, Fontana A, Boiardi L et al (2019) The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. J Autoimmun 98:113–121PubMedCrossRef

160.

Tsai HC, Nguyen K, Hashemi E, Engleman E, Hla T, Han MH (2019) Myeloid sphingosine-1-phosphate receptor 1 is important for CNS autoimmunity and neuroinflammation. J Autoimmun 105:102290PubMedCrossRef

161.

Alexopoulos H, Dalakas MC (2019) The immunobiology of autoimmune encephalitides. J Autoimmun 104:102339PubMedCrossRef

162.

Bronge M, Ruhrmann S, Carvalho-Queiroz C, Nilsson OB, Kaiser A, Holmgren E et al (2019) Myelin oligodendrocyte glycoprotein revisited-sensitive detection of MOG-specific T-cells in multiple sclerosis. J Autoimmun 102:38–49PubMedCrossRef

163.

Mattapallil MJ, Kielczewski JL, Zarate-Blades CR, St Leger AJ, Raychaudhuri K, Silver PB et al (2019) Interleukin 22 ameliorates neuropathology and protects from central nervous system autoimmunity. J Autoimmun 102:65–76PubMedPubMedCentralCrossRef

164.

Brate AA, Boyden AW, Itani FR, Pewe LL, Harty JT, Karandikar NJ (2019) Therapeutic intervention in relapsing autoimmune demyelinating disease through induction of myelin-specific regulatory CD8 T cell responses. J Transl Autoimmun 2

165.

Shemer A, Willis R, Gonzalez EB, Romay-Penabad Z, Shovman O, Shoenfeld Y et al (2019) Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome. J Autoimmun 99:98–103PubMedCrossRef

166.

Qureshi MS, Alsughayyir J, Chhabra M, Ali JM, Goddard MJ, Devine CA et al (2019) Germinal center humoral autoimmunity independently mediates progression of allograft vasculopathy. J Autoimmun 98:44–58PubMedCrossRef

167.

Alvarez-Sierra D, Marin-Sanchez A, Ruiz-Blazquez P, de Jesus GC, Iglesias-Felip C, Gonzalez O et al (2019) Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun 103:102285PubMedCrossRef

168.

Das T, Bergen IM, Koudstaal T, van Hulst JAC, van Loo G, Boonstra A et al (2019) DNGR1-mediated deletion of A20/Tnfaip3 in dendritic cells alters T and B-cell homeostasis and promotes autoimmune liver pathology. J Autoimmun 102:167–178PubMedCrossRef

169.

Terziroli Beretta-Piccoli B, Di Bartolomeo C, Deleonardi G, Grondona AG, Silvestri T, Tesei C et al (2019) Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. J Autoimmun 102:89–95PubMedCrossRef

170.

Huynh M, Eggenhuizen PJ, Olson GL, Rao NB, Self CR, Sun Y et al (2019) HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen. J Autoimmun 103:102276PubMedCrossRef

171.

Stremska ME, Dai C, Venkatadri R, Wang H, Sabapathy V, Kumar G et al (2019) IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent. J Autoimmun 102:133–141PubMedPubMedCentralCrossRef

172.

Kolb H, Burkart V (2019) Chaperones may cause the focus of diabetes autoimmunity on distinct (pro)insulin peptides. J Autoimmun 105:102304PubMedCrossRef

173.

Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J et al (2019) Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun 103:102289PubMedCrossRef

174.

Simakou T, Butcher JP, Reid S, Henriquez FL (2019) Alopecia areata: a multifactorial autoimmune condition. J Autoimmun 98:74–85PubMedCrossRef

175.

Erdei E, Shuey C, Pacheco B, Cajero M, Lewis J, Rubin RL (2019) Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation. J Autoimmun 99:15–23PubMedPubMedCentralCrossRef

176.

Meier HCS, Parks CG, Liu HB, Sandler DP, Simonsick EM, Deane K et al (2019) Cellular aging over 13 years associated with incident antinuclear antibody positivity in the Baltimore Longitudinal Study of Aging. J Autoimmun 105:102295PubMedCrossRefPubMedCentral

177.

Essouma M, Nkeck JR, Endomba FT, Bigna JJ, Singwe-Ngandeu M, Hachulla E (2020) Systemic lupus erythematosus in Native sub-Saharan Africans: a systematic review and meta-analysis. J Autoimmun 106:102348PubMedCrossRef

178.

Tanner S, Dufault B, Smolik I, Meng X, Anaparti V, Hitchon C et al (2019) A prospective study of the development of inflammatory arthritis in the family members of indigenous North American people with rheumatoid arthritis. Arthritis Rheum 71:1494–1503CrossRef

179.

Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J et al (2019) Association of geography and access to health care providers with long-term prescription opioid use in Medicare patients with severe osteoarthritis: a cohort study. Arthritis Rheum 71:712–721CrossRef

180.

Kronzer VL, Crowson CS, Sparks JA, Vassallo R, Davis JM 3rd. (2019) Investigating asthma, allergic disease, passive smoke exposure, and risk of rheumatoid arthritis. Arthritis Rheum 71:1217–1224CrossRef

181.

Liu X, Tedeschi SK, Lu B, Zaccardelli A, Speyer CB, Costenbader KH et al (2019) Long-term pysical activity and subsequent risk for rheumatoid arthritis among women: a prospective cohort study. Arthritis Rheum 71:1460–1471CrossRef

182.

Lee YC, Kremer J, Guan H, Greenberg J, Solomon DH (2019) Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheum 71:670–677CrossRef

183.

Chang C, Gershwin ME (2019) The myth of mycotoxins and mold injury. Clin Rev Allergy Immunol 57:449–455PubMedCrossRef

184.

Yamamoto E, Jorgensen TN (2019) Immunological effects of vitamin D and their relations to autoimmunity. J Autoimmun 100:7–16PubMedCrossRef

185.

Huang C, Yi X, Long H, Zhang G, Wu H, Zhao M et al (2020) Disordered cutaneous microbiota in systemic lupus erythematosus. J Autoimmun 108:102391PubMedCrossRef

186.

van der Meulen TA, Harmsen HJM, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A et al (2019) Shared gut, but distinct oral microbiota composition in primary Sjogren's syndrome and systemic lupus erythematosus. J Autoimmun 97:77–87PubMedCrossRef

187.

Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME (2019) Primary immunodeficiency and autoimmunity: a comprehensive review. J Autoimmun 99:52–72PubMedCrossRef

188.

Jamee M, Moniri S, Zaki-Dizaji M, Olbrich P, Yazdani R, Jadidi-Niaragh F et al (2019) Clinical, immunological, and genetic features in patients with activated PI3K delta syndrome (APDS): a systematic review. Clin Rev Allergy Immunol

189.

Gokhale AS, Gangaplara A, Lopez-Occasio M, Thornton AM, Shevach EM (2019) Selective deletion of Eos (Ikzf4) in T-regulatory cells leads to loss of suppressive function and development of systemic autoimmunity. J Autoimmun 105:102300PubMedCrossRef

190.

Lourou N, Gavriilidis M, Kontoyiannis DL (2019) Lessons from studying the AU-rich elements in chronic inflammation and autoimmunity. J Autoimmun 104:102334PubMedCrossRef

191.

Lundtoft C, Seyfarth J, Oberstrass S, Rosenbauer J, Baechle C, Roden M et al (2019) Autoimmunity risk- and protection-associated IL7RA genetic variants differentially affect soluble and membrane IL-7R alpha expression. J Autoimmun 97:40–47PubMedCrossRef

192.

Morianos I, Papadopoulou G, Semitekolou M, Xanthou G (2019) Activin-A in the regulation of immunity in health and disease. J Autoimmun 104:102314PubMedCrossRef

193.

Pacheco Y, Acosta-Ampudia Y, Monsalve DM, Chang C, Gershwin ME, Anaya JM (2019) Bystander activation and autoimmunity. J Autoimmun 103:102301PubMedCrossRef

194.

Saferding V, Bluml S (2020) Innate immunity as the trigger of systemic autoimmune diseases. J Autoimmun 110:102382PubMedCrossRef

195.

Vlachiotis S, Andreakos E (2019) Lambda interferons in immunity and autoimmunity. J Autoimmun 104:102319PubMedCrossRef

196.

Yao L, Zhou L, Xuan Y, Zhang P, Wang X, Wang T et al (2019) The proteasome activator REG gamma counteracts immunoproteasome expression and autoimmunity. J Autoimmun 103:102282PubMedCrossRef

197.

Chen B, Vousden KA, Naiman B, Turman S, Sun H, Wang S et al (2019) Humanised effector-null Fc gamma RIIA antibody inhibits immune complex-mediated proinflammatory responses. Ann Rheum Dis 78:228–237PubMedCrossRef

198.

Stohl W, Yu N, Chalmers S, Putterman C, Jacob CO (2020) Development of murine systemic lupus erythematosus in the absence of BAFF. Arthritis Rheum 72:292–302CrossRef

199.

Xiao N, Wei J, Xu S, Du H, Huang M, Zhang S et al (2019) cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model. J Autoimmun 100:84–94PubMedCrossRef

200.

Wade SM, Trenkmann M, McGarry T, Canavan M, Marzaioli V, Wade SC et al (2019) Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B. J Autoimmun 96:86–93PubMedCrossRef

201.

Mustelin T, Bottini N, Stanford SM (2019) The contribution of PTPN22 to rheumatic disease. Arthritis Rheum 71:486–495CrossRef

202.

Tison A, Quere G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheum 71:2100–2111CrossRef

203.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P (2019) Balancing cancer immunotherapy and immune-related adverse events: the emerging role of regulatory T cells. J Autoimmun 104:102310PubMedCrossRef

204.

Thiel J, Alter C, Luppus S, Eckstein A, Tan S, Fuhrer D et al (2019) MicroRNA-183 and microRNA-96 are associated with autoimmune responses by regulating T cell activation. J Autoimmun 96:94–103PubMedCrossRef

205.

Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P (2019) JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 18:102390PubMedCrossRef

Title: Autoimmunity in 2019
Author: Carlo Selmi
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Systemic Lupus Erythematosus
Psoriatic Arthritis
Rheumatoid Arthritis
Published in: Clinical Reviews in Allergy & Immunology / Issue 3/2020
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-020-08808-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Equine Hypersensitivity: the Dark Horse of Allergy

Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review

Clinical Characteristics and Risk Factors of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis Based on Observational Studies

Systemic Amyloidosis: a Contemporary Overview

JAK Inhibitors: Prospects in Connective Tissue Diseases

The Aryl Hydrocarbon Receptor (AHR) as a Potential Target for the Control of Intestinal Inflammation: Insights from an Immune and Bacteria Sensor Receptor

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials